Irazu Bio
Translational life‑science firm that partners with academic principal investigators and university centers to advance IND‑enabling studies and Phase I clinical trials. Activities include curation and commercialization of academic IP, licensing or company formation with industry and investors, and development of biologic and immuno‑oncology therapeutic platforms including gene therapy process development and AAV manufacturing.
Industries
Nr. of Employees
small (1-50)
Irazu Bio
801 W. Baltimore Street, Suite 518, Baltimore, MD 21201
Products
Academic Partnerships
Collaborates with Principal Investigators and university-based Centers of Excellence to accelerate translational research into IND-enabling studies and Phase 1 clinical trials.
Research Curation
Increases value for intellectual property assets through a hands-on approach.
Business Model
Licenses with pharma companies for clinical development of IP assets or starts new companies with venture capital groups.
Hypoxia Tolerance And NeuroProtection
Leverages biochemical mechanisms for potential applications in survival, disease prevention, and life quality improvement in old age.
Immuno-Oncology
Develops 'Bugs as Drugs' for cancer treatment by inducing global immunity targeting unique tumor antigens.
Adeno-Associated Virus (AAV) Gene Therapy
Focuses on gene therapy process development and manufacturing for rare and orphan diseases.
Academic Partnerships
Collaborates with Principal Investigators and university-based Centers of Excellence to accelerate translational research into IND-enabling studies and Phase 1 clinical trials.
Research Curation
Increases value for intellectual property assets through a hands-on approach.
Business Model
Licenses with pharma companies for clinical development of IP assets or starts new companies with venture capital groups.
Hypoxia Tolerance And NeuroProtection
Leverages biochemical mechanisms for potential applications in survival, disease prevention, and life quality improvement in old age.
Immuno-Oncology
Develops 'Bugs as Drugs' for cancer treatment by inducing global immunity targeting unique tumor antigens.
Adeno-Associated Virus (AAV) Gene Therapy
Focuses on gene therapy process development and manufacturing for rare and orphan diseases.
Services
Collaborative engagements with investigators and university centers to translate discoveries toward clinical development.
Support and coordination of preclinical studies required for regulatory filings and early‑phase clinical execution.
Evaluation, vetting and value enhancement of academic intellectual property to prepare assets for licensing or company formation.
Structuring of licensing deals with pharma or forming new companies with venture partners to advance clinical development.
Process development and manufacturing capabilities for AAV gene therapy vectors.
R&D and platform development for microbial‑based immunotherapies targeting tumor antigens.
Collaborative engagements with investigators and university centers to translate discoveries toward clinical development.
Support and coordination of preclinical studies required for regulatory filings and early‑phase clinical execution.
Evaluation, vetting and value enhancement of academic intellectual property to prepare assets for licensing or company formation.
Structuring of licensing deals with pharma or forming new companies with venture partners to advance clinical development.
Process development and manufacturing capabilities for AAV gene therapy vectors.
R&D and platform development for microbial‑based immunotherapies targeting tumor antigens.
Expertise Areas
- Translational research and clinical acceleration
- IND‑enabling preclinical studies
- Phase I clinical trial support
- Gene therapy process development and manufacturing
Key Technologies
- AAV vector manufacturing
- Gene therapy process development
- Microbial‑based therapeutics ("bugs as drugs")
- Immuno‑oncology platform development